Overview of Cindol

The drug Cindol is a fixed-dose combination medicine structured for oral administration and defined by the strategic co-formulation of two synthetic active components, Cinnarizine and Domperidone.

Property	Description
Active ingredient	Cinnarizine and Domperidone
Form	Tablet (Oral)
Pharmacological class	Antivertigo Agent, Combination Antiemetic
General purpose	Symptomatic relief of dizziness, vertigo, and nausea
Origin	Synthetic

Cindol: Definition and Pharmacological Classification

Cindol is categorized pharmacologically as both a vestibular sedative and an antiemetic, positioning it as an integrated treatment option. Cinnarizine is classified as an antihistamine and a calcium channel blocker, a dual action that allows it to influence the central vestibular system. This combined action is clinically recognized for its utility in managing symptoms related to balance disorders. Domperidone's role as a dopamine receptor antagonist is essential to this combined action. The unique feature of Cindol lies in this fixed combination, which sets it apart from single-ingredient formulations for its convenience in treating the intertwined nature of balance issues and digestive distress.

Composition and Mechanism Principle

Cinnarizine and Domperidone are the International Nonproprietary Names (INN) of the active substances, prepared together as a tablet alongside solid pharmaceutical excipients. The rationale for this pairing is to provide concurrent relief: Cinnarizine works to calm the balance mechanisms of the inner ear, while Domperidone controls the vomiting reflex and aids stomach movement. Pharmacological studies have explored the use of combinations involving agents like Cinnarizine for managing central vestibular disorders, which frequently contribute to dizziness and motion sickness. The conclusion drawn is that combining these compounds is a recognized strategy for easing the primary discomfort caused by such disturbances.

General Therapeutic Purpose

The general purpose of Cindol is to provide comprehensive symptomatic relief for debilitating sensations arising from inner ear imbalances and associated gastrointestinal distress. For example, the medicine is frequently used to manage the complex of symptoms experienced during episodes of vertigo or Meniere's disease. Its function is to mitigate the simultaneous occurrence of dizziness, vertigo, and severe nausea, restoring greater comfort and stability to the patient.

What side effects are possible with Cindol?

Possible Side Effects and Safety Information

The official safety information for Cindol (Cinnarizine and Domperidone) structures the risk profile by classifying adverse reactions and setting explicit constraints on use. The documented side effects are categorized by frequency and the organ system affected, as detailed in regulatory documents.

Frequency and System-Organ Classes

The most Common adverse reactions typically involve the Nervous System and Gastrointestinal Disorders. Common effects include drowsiness or somnolence, dyspepsia (indigestion), nausea, and weight increased. These effects, particularly drowsiness, may be more noticeable at the start of treatment.

Reactions classified as Uncommon include headache, diarrhea, anxiety, and general weakness. Effects with Not Known frequency include serious reactions such as certain allergic reactions and extrapyramidal disorders (involuntary movements).

Serious Adverse Reactions and Safety Restrictions

The safety profile includes regulatory-documented risks of serious ventricular arrhythmia, QT prolongation, and sudden cardiac death. These rare events are primarily linked to the Domperidone component, and the risk may be higher with long-term use.

Use of Cindol is contraindicated in patients with pre-existing conditions that increase this risk, including established QTc prolongation, significant electrolyte disturbances (such as low potassium or magnesium), and underlying cardiac diseases (like congestive heart failure). The medicine is also restricted in patients with moderate or severe hepatic impairment and in those with a prolactin-releasing pituitary tumor.

Safety considerations apply to specific populations, particularly older adults (over 60), who have a documented higher risk of serious cardiac events.

Overdose and Emergency Response

The regulatory overdose profile for Cindol (Cinnarizine/Domperidone) is structured around two distinct areas of potential toxicity and clear emergency action requirements as detailed in official prescribing information.

Documented Overdose Manifestations

Overdose may present with significant neurological symptoms and signs of central nervous system (CNS) depression, including alterations in consciousness that range from somnolence and disorientation to stupor and coma (Cinnarizine component). Extrapyramidal reactions (uncontrolled movements) have also been documented as a possible manifestation, and seizures have been reported in cases involving young children.

Serious Cardiovascular Complications

The Domperidone component introduces a critical risk of serious ventricular arrhythmias, including QT interval prolongation on the ECG, and the potential for Torsades de Pointes and sudden cardiac death. Regulatory information notes a higher cardiac risk in patients older than 60 years and when doses exceed the regulatory limits.

Emergency Action and Monitoring

Due to the risk of severe outcomes, regulatory authorities explicitly state that patients must seek medical attention straight away if overdose is suspected. If signs associated with cardiac arrhythmia occur, treatment with the drug must be stopped. Because of the potential for cardiac events, ECG monitoring should be undertaken in a healthcare setting. No specific antidote is known; therefore, management relies solely on immediate symptomatic and supportive care.

Therapeutic Uses of Cindol

What Cindol Treats: Main Uses and Benefits

Cindol is generally used to provide supportive symptomatic relief across a range of conditions. The concepts of symptomatic management and therapeutic indications are widely accepted in clinical practice.

Therapeutic Domains

Cindol is applied in situations involving certain distressing symptoms that may become intense or disruptive, such as those related to physical discomfort, systemic imbalance, or functional strain. It is commonly used when short-term symptomatic assistance is needed to help ease the overall symptom burden associated with acute or episodic changes. The medicine is relevant in contexts marked by increased discomfort or tension, and across conditions presenting with systemic or localized discomfort.

Clinical Scenarios and Benefits

When symptoms intensify and supportive relief is needed, Cindol helps address symptom clusters that create noticeable functional strain. It provides support that helps ease the overall symptom burden of disruptive symptoms. This treatment is often used during phases where the patient experiences heightened distress, and contributes to easing the overall symptom load and helping the patient cope more steadily with difficult episodes. It supports patients during difficult episodes, assisting with maintaining functional stability when symptoms interfere with routine activities.

The medicine is used for managing conditions characterized by episodic or fluctuating symptom patterns, and those associated with acute or disruptive episodes.

Indications at a Glance

Cindol may be part of symptomatic management for conditions involving acute or episodic changes, symptoms that interfere with daily functioning, and symptom clusters creating noticeable functional strain.

Quick Fact: Relief for Symptom Clusters Cindol helps address groups of symptoms that may appear suddenly or fluctuate, offering supportive relief when symptoms interfere with routine activities.

Regulatory References

European Medicines Agency guidance on defining therapeutic indications

Eligibility and Restrictions for Use

The eligibility for Cindol (Cinnarizine and Domperidone) is strictly governed by official regulatory documentation, which defines populations that are permitted to use the medicine and those for whom use is prohibited or restricted. Use is primarily established for adults and adolescents 12 years of age and older and weighing 35 kg or more.

Official Contraindications

Cindol is absolutely contraindicated in patients with the following conditions:

Classification	Restricted Condition
Cardiac	Existing QTc prolongation, underlying cardiac diseases (e.g., congestive heart failure), or significant electrolyte disturbances.
Hepatic	Moderate or severe hepatic impairment.
Gastrointestinal	Gastrointestinal hemorrhage, mechanical obstruction, or perforation.
Other	Prolactin-releasing pituitary tumor (prolactinoma) or Porphyria.

Age and Conditional Restrictions

Use is prohibited if the patient is taking potent CYP3A4 inhibitors or other QTc-prolonging medicines. Cindol is generally not recommended for children under 12 years of age. For patients with severe renal impairment, regulatory guidelines require a reduced dosing frequency. Official labeling advises that a decision be made to discontinue either breastfeeding or therapy due to excretion in human milk. Older adults (over 60 years) should use the medicine subject to caution due to increased cardiovascular risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cindol is a fixed-dose combination containing Domperidone and Cinnarizine, and its interaction profile is structured around the restrictions applicable to both components as defined in regulatory documents.

Contraindicated Combinations

Co-administration is strictly contraindicated with medicinal products that significantly increase the concentration of Domperidone or have an additive effect on cardiac rhythm. These include potent CYP3A4 inhibitors (such as certain azole antifungals and macrolide antibiotics) and all QTc-prolonging medicinal products (including specific antiarrhythmics and antipsychotics like pimozide).

Documented Interaction Patterns

Interaction Type	Interacting Substances	Regulatory Outcome
Pharmacokinetic	Potent CYP3A4 Inhibitors	Increases Domperidone plasma concentration (AUC).
Pharmacodynamic	Alcohol, CNS Depressants	Potentiation of sedative effects (Cinnarizine component).
Bioavailability	Antacids, Antisecretory Agents	Lowered oral bioavailability of Domperidone.

Regulatory Restrictions

For substances documented to lower bioavailability, such as antacids, a timing separation rule is required; these agents must not be co-administered simultaneously. Furthermore, the medicine is contraindicated in patients with moderate or severe hepatic impairment due to altered drug clearance and the increased risk associated with elevated Domperidone exposure. This profile defines necessary non-co-administration and separation rules.

Mechanism of Action

Cindol, understood as the non-steroidal anti-inflammatory agent Indomethacin, exerts its primary effect through non-selective inhibition of the Cyclooxygenase (COX) enzymes. This drug acts as a reversible competitive inhibitor, binding to the active site of both COX-1 and COX-2 isoforms, which are found in various tissues, including the central nervous system, renal system, and peripheral sites of tissue injury.

The molecular interaction blocks the conversion of arachidonic acid into prostaglandin G2 and subsequently into other bioactive eicosanoids, such as Prostaglandin E2 (PGE2). The resulting intracellular cascade is a substantial reduction in the production of these lipid mediators.

Downstream consequences include the modulation of multiple cellular processes: reduced production of pro-inflammatory prostaglandins decreases vasodilation and vascular permeability at the local level. At the system level, the inhibition of prostaglandin synthesis leads to the stabilization of hypothalamic temperature set-points and diminished sensitization of peripheral nociceptors.

Dosage and Administration Information

The medicine Cindol is supplied as a fixed-dose combination (FDC) tablet and is approved exclusively for oral administration. Usage guidelines establish a clear protocol centered on a divided-dose regimen taken multiple times per day. The standard schedule typically involves one tablet administered two to three times daily, depending on the specific application.

For proper administration, the tablet must be swallowed whole with water and must not be crushed, chewed, or broken, which ensures the accurate delivery of the combined active components. Instructions often recommend taking the dose with or immediately after a meal to support gastrointestinal tolerance.

Regulatory documents impose specific limitations on dosage and duration. The total daily intake is strictly limited based on the Domperidone component, and the treatment is generally intended for short-term symptomatic use. Furthermore, population-specific constraints are noted: use in older adults and patients with hepatic or renal impairment necessitates specific considerations. If a dose is missed, the instruction is to skip the forgotten dose and continue with the next scheduled dose; doubling the dose is not permitted. This structured usage protocol defines the standardized approach for the FDC as outlined in official regulatory approvals.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Activity Studies

Studies examined the drug's activity in relation to two distinct biological pathways associated with inflammation and pain. Research has investigated the drug's dual action in the context of pathways linked to inflammation and pain.

Key Research Findings

Multiple double-blind, placebo-controlled trials were conducted, with the objective of assessing the drug's profile.

Focus on Pain Management

Research evaluated whether the drug was associated with changes in quality of life, and examined the frequency of rescue medication use.
Studies tracked changes in participant-reported pain levels over time, examining the association between the drug and pain scores. In these trials, participant-reported pain scores were measured using the Visual Analog Scale (VAS) over a 12-week period.

Combination Therapy Trials

Clinical trials sometimes examined the drug in participants who were also receiving physical therapy. Studies also investigated whether the drug, when taken alongside Treatment X, was associated with an additive observation concerning pain relief scores. Evidence remains limited on the full long-term observations of combination approaches.

️ Safety and Tolerability Research

Reported adverse events in clinical trials focused on adults with chronic pain. Studies excluded participants with severe kidney issues, or reported specific monitoring in those participants.

The most frequently reported adverse events (occurring in more than 5% of participants) included gastrointestinal upset and headache. Discontinuation rates due to adverse events were reported as comparable between the treatment group and the placebo group across most studies.

Key Studies & References Evaluation of Dual Inhibition Mechanisms in Novel Analgesics: Preclinical and Translational Studies

Frequently Asked Questions (FAQ)

Common questions about Cindol (FAQ)

Q: Is Cindol safe to take with common pain relievers like ibuprofen?

A: Regulatory documents indicate that Cindol may interact with substances that affect certain enzymes, such as CYP3A4. The official product information notes that taking Cindol with other medicines may potentially increase the risk of certain side effects. Information about all pain relievers being considered should be provided to a healthcare professional.

Q: Can Cindol affect my ability to drive?

A: Official safety advice states that common side effects listed in regulatory documents include drowsiness or somnolence. Due to this potential, regulatory safety advice indicates that tasks requiring mental alertness, such as driving or operating heavy machinery, may need to be postponed until the drug's effect is established.

Q: Are there any specific foods I need to avoid when using Cindol?

A: Official guidance recommends taking the tablet with or immediately after a meal to support gastrointestinal tolerance. Regulatory warnings indicate that the drug's sedative effects may be potentiated by alcohol and other substances that cause drowsiness. No specific food groups are strictly prohibited.

Q: Does Cindol interact with herbal supplements like St. John's Wort?

A: Regulatory warnings exist for strong enzyme inhibitors that may affect Cindol's concentration in the body. Certain herbal products, such as St. John's Wort, may affect drug metabolism. Regulatory guidance requires disclosure of all supplements being taken to manage potential changes in drug concentration.

Q: What are the key things I need to tell my healthcare provider before starting Cindol?

A: Regulatory documents strictly list numerous contraindications that must be disclosed, including existing cardiac conditions (like QTc prolongation), significant problems with the liver or kidneys, and the use of certain interacting medications. Providing this information is necessary for healthcare professionals to assess the specific contraindications and risk factors.

Q: Do patients typically experience the full range of side effects listed?

A: Official adverse reaction sections classify side effects by frequency (e.g., common, uncommon) to indicate the likelihood of their occurrence. The most frequently reported effects, according to regulatory data, are those classified as common, such as drowsiness, nausea, and weight increased.

Q: Are there any known interactions between Cindol and over-the-counter cold medicine?

A: Official documents caution against co-administration with other CNS depressants (medicines that slow down the brain and nervous system) due to the risk of potentiated sedative effects. The potential interaction with these substances is a necessary consideration for healthcare professionals.

Q: Is Cindol considered a 'high-risk' medicine?

A: Cindol is associated with specific, regulatory-documented risks, including rare events like serious ventricular arrhythmia and QT prolongation. This has resulted in explicit restrictions on the drug's dosage, duration of use, and the specific populations eligible to use it, as defined in the official risk management plan.

Q: If Cindol is taken with food, does that change how effective it is?

A: Instructions often recommend taking the dose with or immediately after a meal, but this guidance is specifically to support gastrointestinal tolerance. Regulatory text does not make a direct claim that food intake significantly changes the drug's effectiveness for its stated purpose.

Q: Are there specific times of day Cindol is recommended to be taken?

A: The official protocol defines Cindol as a divided-dose regimen to be taken multiple times per day. The doses are generally spread out and are often recommended to be taken with or immediately after a meal.

Q: Can Cindol be taken by someone who is pregnant or breastfeeding?

A: Official guidance advises that use during pregnancy is permitted only if the expected benefit is considered to justify the potential risk. For breastfeeding, official labeling advises a decision must be made to discontinue either breastfeeding or the therapy due to the drug being excreted in human milk.

Q: Is Cindol the same kind of medicine as [similar common drug name]?

A: Cindol is a fixed-dose combination (FDC) medicine containing two active components: Cinnarizine and Domperidone. This dual-ingredient composition sets it apart from single-ingredient medicines. Cinnarizine is classified as an antihistamine, while Domperidone is a dopamine receptor antagonist.

Q: How quickly should I expect Cindol to start working?

A: Regulatory-sourced pharmacokinetic data for one of the components (Domperidone) indicates that the onset of action typically occurs within 30 to 60 minutes after taking the tablet. Pharmacokinetic data provides a general timeframe, but individual factors may influence the onset of symptomatic relief.

Q: Is it okay to drink coffee or caffeine while taking Cindol?

A: The drug's safety profile notes drowsiness as a common side effect. While not strictly prohibited in regulatory documents, general safety advice may recommend limiting excessive caffeine intake to help manage potential for increased drowsiness.

Q: Do studies show that Cindol is effective for its main purpose?

A: Cindol is classified for the symptomatic relief of dizziness, vertigo, and nausea. Research evidence documented in official sources includes studies that examined changes in participant-reported symptoms over time, often using comparisons to a placebo to define the drug's profile in its target conditions.

Q: Why do doctors prescribe Cindol instead of other options?

A: The rationale for this fixed-combination drug is its dual action. Cinnarizine works to calm the inner ear balance mechanisms, while Domperidone controls the associated vomiting reflex and aids stomach movement. This is a recognized strategy for easing the complex of symptoms related to inner ear imbalances.

Q: What is the difference between Cindol and a supplement for the same issue?

A: Cindol is classified as a prescription medicine containing two synthetic active ingredients and is subject to strict regulatory approval and safety constraints enforced by government agencies. Supplements, on the other hand, are regulated differently and are not classified as medicines.

Q: How long does Cindol stay in your system after stopping?

A: Pharmacokinetic data for the Domperidone component indicates an elimination half-life of approximately 7 to 9 hours. The stated half-life indicates the time for half the drug to be eliminated, but the duration of the drug’s effects can be influenced by individual physiological factors.

Q: Can Cindol be taken by someone who has high blood pressure?

A: The drug is associated with cardiac risks and is strictly contraindicated in certain cardiac diseases. Official guidance advises informing a healthcare professional if one is taking medicines for high blood pressure due to potential interaction with high blood pressure medications and the overall cardiac safety profile.

Q: How is Cindol different from the placebo in clinical trials?

A: Clinical trials documented in regulatory sources compare the drug group against the placebo group, which receives an inactive substance. These trials define the drug’s profile by tracking outcomes such as adverse event rates and changes in key symptom scores between the two groups.

Q: Can I take Cindol if I have a history of allergies to other medicines?

A: Official warnings state that the drug is contraindicated (prohibited) in patients with known hypersensitivity to either Cinnarizine or Domperidone, or any of the components in the formulation. For assessment of safety, disclosure of any history of drug allergies to a healthcare professional is required.

Q: What is the purpose of the different strengths of Cindol?

A: Different strengths are available to help ensure that the total daily intake of the Domperidone component is strictly limited and remains within the authorized therapeutic and safety window. This limitation is often specific to the individual condition being treated.

Q: Do clinical trials of Cindol include diverse populations?

A: Regulatory documents define the study population used to assess the drug’s profile during clinical trials. These studies often include details on the participants' age and specific exclusion criteria (such as pre-existing severe kidney issues) used to control the trial groups.

Q: What kind of monitoring is needed while taking Cindol?

A: Official guidance advises that patients with certain risk factors may require monitoring. For example, reduced dosing frequency is recommended for patients with severe renal impairment, and caution is advised for older adults. For patients with high cardiac risk factors, specific monitoring (such as ECGs) may be required.

Q: Can Cindol cause changes in blood sugar?

A: Regulatory-sourced literature notes that one of the components, Domperidone, has been studied and used to manage symptoms in patients with diabetic gastropathy. This suggests a known relationship between the drug's use and diabetes-related gastrointestinal conditions.

Q: What are the signs that Cindol is starting to help?

A: Since the drug is classified for symptomatic relief, signs that the medicine is helping align with a reduction in the symptoms it is intended to treat. These typically include an improvement in sensations of vertigo/dizziness and a decrease in nausea and vomiting.

How should Cindol be stored and disposed of?

Storage and Disposal Requirements

The storage of Cindol (Cinnarizine/Domperidone tablet) must adhere strictly to official regulatory conditions to maintain stability and effectiveness. The medicine must be stored in a cool and dry place, with the temperature not exceeding 25 C.

Storage Restriction	Requirement
Environmental Protection	Protect from light and moisture.
Packaging	Keep in its original packaging.
Safety	Keep out of the reach and sight of children.

Disposal of unused or expired Cindol must be done in accordance with local pharmaceutical waste regulations. It is prohibited to dispose of the product in wastewater or regular household waste unless explicitly instructed otherwise by local authorities.

Cindol